Measured Wealth Private Client Group LLC Buys Shares of 3,158 CVS Health Co. (NYSE:CVS)

Measured Wealth Private Client Group LLC purchased a new stake in CVS Health Co. (NYSE:CVS) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,158 shares of the pharmacy operator’s stock, valued at approximately $252,000.

Several other hedge funds also recently modified their holdings of the company. Atticus Wealth Management LLC raised its position in shares of CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 219 shares during the last quarter. USA Financial Formulas lifted its stake in shares of CVS Health by 573.2% in the 4th quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 321 shares during the period. Ables Iannone Moore & Associates Inc. acquired a new stake in CVS Health during the fourth quarter worth approximately $32,000. Creekmur Asset Management LLC bought a new stake in CVS Health in the fourth quarter worth approximately $34,000. Finally, Steph & Co. lifted its stake in CVS Health by 192.0% in the first quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock valued at $35,000 after buying an additional 288 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $57.52 on Wednesday. The company’s fifty day moving average is $59.34 and its 200 day moving average is $70.02. The company has a quick ratio of 0.61, a current ratio of 0.81 and a debt-to-equity ratio of 0.78. CVS Health Co. has a 52 week low of $52.77 and a 52 week high of $83.25. The stock has a market cap of $72.21 billion, a PE ratio of 10.11, a PEG ratio of 0.56 and a beta of 0.52.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion during the quarter, compared to the consensus estimate of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The company’s revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm posted $2.20 EPS. Research analysts anticipate that CVS Health Co. will post 7.02 earnings per share for the current year.

Insider Activity at CVS Health

In other news, Director Edward J. Ludwig acquired 1,000 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were purchased at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the transaction, the director now owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.24% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on CVS shares. Barclays lowered their price objective on shares of CVS Health from $78.00 to $63.00 and set an “equal weight” rating for the company in a research note on Thursday, May 2nd. Piper Sandler upped their price target on CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Truist Financial reissued a “buy” rating and issued a $66.00 price objective (down previously from $90.00) on shares of CVS Health in a research note on Thursday, May 2nd. SVB Leerink reiterated a “market perform” rating and issued a $60.00 target price (down from $87.00) on shares of CVS Health in a report on Wednesday, May 1st. Finally, UBS Group lowered shares of CVS Health from a “buy” rating to a “neutral” rating and decreased their price target for the company from $85.00 to $60.00 in a research note on Thursday, May 2nd. Eleven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $75.05.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.